Jordi ClarimÃ³n

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5661962/publications.pdf

Version: 2024-02-01

215 papers	18,583 citations	28190 55 h-index	17055 122 g-index
240 all docs	240 docs citations	240 times ranked	21829 citing authors

#	Article	IF	Citations
1	Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nature Genetics, 2013, 45, 1452-1458.	9.4	3,741
2	Genetic meta-analysis of diagnosed Alzheimerâ€™s disease identifies new risk loci and implicates AÎ², tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	9.4	1,962
3	Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet Neurology, The, 2019, 18, 1091-1102.	4.9	1,414
4	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	9.4	783
5	New insights into the genetic etiology of Alzheimerâ€™s disease and related dementias. Nature Genetics, 2022, 54, 412-436.	9.4	700
6	A novel GSK-3Î² inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo. Neurobiology of Disease, 2009, 35, 359-367.	2.1	309
7	Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurology, The, 2014, 13, 686-699.	4.9	302
8	Trading Genes along the Silk Road: mtDNA Sequences and the Origin of Central Asian Populations. American Journal of Human Genetics, 1998, 63, 1824-1838.	2.6	295
9	A novel Alzheimer disease locus located near the gene encoding tau protein. Molecular Psychiatry, 2016, 21, 108-117.	4.1	260
10	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nature Genetics, 2021, 53, 294-303.	9.4	198
11	Genetic screening of Alzheimer's disease genes in Iberian and African samples yields novel mutations in presenilins and APP. Neurobiology of Aging, 2010, 31, 725-731.	1.5	196
12	Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. Lancet Neurology, The, 2018, 17, 64-74.	4.9	195
13	Convergent genetic and expression data implicate immunity in Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 658-671.	0.4	173
14	The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimerâ€™s disease risk. Science Translational Medicine, 2019, 11, .	5.8	170
15	Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. Lancet, The, 2020, 395, 1988-1997.	6.3	164
16	Gene-Wide Analysis Detects Two New Susceptibility Genes for Alzheimer's Disease. PLoS ONE, 2014, 9, e94661.	1.1	155
17	Glucocerebrosidase mutations confer a greater risk of dementia during Parkinson's disease course. Movement Disorders, 2012, 27, 393-399.	2.2	144
18	Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. Lancet Neurology, The, 2018, 17, 860-869.	4.9	140

#	Article	IF	Citations
19	Common variants in Alzheimerâ€™s disease and risk stratification by polygenic risk scores. Nature Communications, 2021, 12, 3417.	5.8	140
20	Confluence of Î±-Synuclein, Tau, and Î²-Amyloid Pathologies in Dementia With Lewy Bodies. Journal of Neuropathology and Experimental Neurology, 2013, 72, 1203-1212.	0.9	138
21	Missense mutations inTENM4, a regulator of axon guidance and central myelination, cause essential tremor. Human Molecular Genetics, 2015, 24, 5677-5686.	1.4	134
22	Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease. Neurology, 2015, 85, 626-633.	1.5	131
23	Dementia Risk in Parkinson Disease. Archives of Neurology, 2011, 68, 359-64.	4.9	125
24	Cortical microstructural changes along the Alzheimer's disease continuum. Alzheimer's and Dementia, 2018, 14, 340-351.	0.4	122
25	Sex-Specific Migration Patterns in Central Asian Populations, Revealed by Analysis of Y-Chromosome Short Tandem Repeats and mtDNA. American Journal of Human Genetics, 1999, 65, 208-219.	2.6	119
26	Tau Enhances Î±-Synuclein Aggregation and Toxicity in Cellular Models of Synucleinopathy. PLoS ONE, 2011, 6, e26609.	1.1	115
27	Changes in Synaptic Proteins Precede Neurodegeneration Markers in Preclinical Alzheimer's Disease Cerebrospinal Fluid. Molecular and Cellular Proteomics, 2019, 18, 546-560.	2.5	115
28	Genomeâ€wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: The GR@ACE project. Alzheimer's and Dementia, 2019, 15, 1333-1347.	0.4	111
29	Cerebrospinal fluid Î²â€amyloid and phosphoâ€tau biomarker interactions affecting brain structure in preclinical Alzheimer disease. Annals of Neurology, 2014, 76, 223-230.	2.8	110
30	Relationship Between Î²-Secretase, Inflammation and Core Cerebrospinal Fluid Biomarkers for Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 42, 157-167.	1.2	106
31	Genetic structure of north-west Africa revealed by STR analysis. European Journal of Human Genetics, 2000, 8, 360-366.	1.4	104
32	Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse. Annals of Clinical and Translational Neurology, 2019, 6, 1815-1824.	1.7	104
33	Tyrosinase exacerbates dopamine toxicity but is not genetically associated with Parkinson's disease. Journal of Neurochemistry, 2005, 93, 246-256.	2.1	103
34	Distinct patterns of APP processing in the CNS in autosomal-dominant and sporadic Alzheimer disease. Acta Neuropathologica, 2013, 125, 201-213.	3.9	103
35	CSF sAPPÎ², YKL-40, and neurofilament light in frontotemporal lobar degeneration. Neurology, 2017, 89, 178-188.	1.5	100
36	YKL-40 (Chitinase 3-like I) is expressed in a subset of astrocytes in Alzheimerâ€™s disease and other tauopathies. Journal of Neuroinflammation, 2017, 14, 118.	3.1	99

#	Article	IF	Citations
37	Characterization of the repeat expansion size in C9orf72 in amyotrophic lateral sclerosis and frontotemporal dementia. Human Molecular Genetics, 2014, 23, 749-754.	1.4	98
38	Identification of Candidate Parkinson Disease Genes by Integrating Genome-Wide Association Study, Expression, and Epigenetic Data Sets. JAMA Neurology, 2021, 78, 464.	4.5	95
39	Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration. Acta Neuropathologica, 2014, 128, 397-410.	3.9	93
40	Assessing the role of the TREM2 p.R47H variant as a risk factor for Alzheimer's disease and frontotemporal dementia. Neurobiology of Aging, 2014, 35, 444.e1-444.e4.	1.5	92
41	APOE-by-sex interactions on brain structure and metabolism in healthy elderly controls. Oncotarget, 2015, 6, 26663-26674.	0.8	92
42	Synaptic phosphorylated Î±-synuclein in dementia with Lewy bodies. Brain, 2017, 140, 3204-3214.	3.7	90
43	Investigation of C9orf72 in 4 Neurodegenerative Disorders. Archives of Neurology, 2012, 69, 1583.	4.9	89
44	TBK1 Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. Human Mutation, 2017, 38, 297-309.	1.1	87
45	A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimerâ€™s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. Acta Neuropathologica, 2019, 138, 237-250.	3.9	87
46	Analysis of theC9orf72Gene in Patients with Amyotrophic Lateral Sclerosis in Spain and Different Populations Worldwide. Human Mutation, 2013, 34, 79-82.	1.1	85
47	A <scp>POGLUT</scp> 1 mutation causes a muscular dystrophy with reduced Notch signaling and satellite cell loss. EMBO Molecular Medicine, 2016, 8, 1289-1309.	3.3	84
48	A comprehensive study of the genetic impact of rare variants in SORL1 in European early-onset Alzheimerâ€™s disease. Acta Neuropathologica, 2016, 132, 213-224.	3.9	83
49	Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study. Alzheimer's and Dementia, 2019, 15, 742-753.	0.4	82
50	Relationship between cortical thickness and cerebrospinal fluid YKL-40 in predementia stages of Alzheimer's disease. Neurobiology of Aging, 2015, 36, 2018-2023.	1.5	75
51	Torsin A haplotype predisposes to idiopathic dystonia. Annals of Neurology, 2005, 57, 765-767.	2.8	73
52	Longitudinal brain structural changes in preclinical Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 499-509.	0.4	65
53	Genetic risk score predicting accelerated progression from mild cognitive impairment to Alzheimerâ€™s disease. Journal of Neural Transmission, 2013, 120, 807-812.	1.4	63
54	Mild cholesterol depletion reduces amyloidâ€Î²2 production by impairing APP trafficking to the cell surface. Journal of Neurochemistry, 2009, 110, 220-230.	2.1	60

#	Article	IF	Citations
55	Genetic variation in APOE cluster region and Alzheimer's disease risk. Neurobiology of Aging, 2011, 32, 2107.e7-2107.e17.	1.5	59
56	CSF sAPPÎ², YKL-40, and NfL along the ALS-FTD spectrum. Neurology, 2018, 91, e1619-e1628.	1.5	59
57	PLD3 in non-familial Alzheimer's disease. Nature, 2015, 520, E3-E5.	13.7	58
58	Penetrance of Parkinson's Disease in LRRK2 p.G2019S Carriers Is Modified by a Polygenic Risk Score. Movement Disorders, 2020, 35, 774-780.	2.2	57
59	Obesity and Alzheimer's disease, does the obesity paradox really exist? A magnetic resonance imaging study. Oncotarget, 2018, 9, 34691-34698.	0.8	57
60	Analysis of theCHCHD10gene in patients with frontotemporal dementia and amyotrophic lateral sclerosis from Spain. Brain, 2015, 138, e400-e400.	3.7	56
61	Shared genetic contribution to ischemic stroke and Alzheimer's disease. Annals of Neurology, 2016, 79, 739-747.	2.8	56
62	A Randomized, Double-blind, Placebo Controlled-trial of Triflusal in Mild Cognitive Impairment. Alzheimer Disease and Associated Disorders, 2008, 22, 21-29.	0.6	55
63	Plasma phosphorylated TDP-43 levels are elevated in patients with frontotemporal dementia carrying a C9orf72 repeat expansion or a GRN mutation. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 684-691.	0.9	55
64	Assessing the role ofDRD5 andDYT1 in two different caseâ€“control series with primary blepharospasm. Movement Disorders, 2007, 22, 162-166.	2.2	54
65	Motor cortex transcriptome reveals microglial key events in amyotrophic lateral sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	54
66	Deleterious ABCA7 mutations and transcript rescue mechanisms in early onset Alzheimerâ€™s disease. Acta Neuropathologica, 2017, 134, 475-487.	3.9	53
67	GBA and APOE Îµ4 associate with sporadic dementia with Lewy bodies in European genome wide association study. Scientific Reports, 2019, 9, 7013.	1.6	53
68	Clinical, Neuropathologic, and Biochemical Profile of the Amyloid Precursor Protein I716F Mutation. Journal of Neuropathology and Experimental Neurology, 2010, 69, 53-59.	0.9	52
69	Nanoscale structure of amyloid-Î² plaques in Alzheimerâ€™s disease. Scientific Reports, 2019, 9, 5181.	1.6	52
70	Weight loss in the healthy elderly might be a non-cognitive sign of preclinical Alzheimer's disease. Oncotarget, 2017, 8, 104706-104716.	0.8	51
71	Conflicting Results Regarding the Semaphorin Gene (SEMA5A) and the Risk for Parkinson Disease. American Journal of Human Genetics, 2006, 78, 1082-1083.	2.6	50
72	Activation of PKR Causes Amyloid ÃŸ-Peptide Accumulation via De-Repression of BACE1 Expression. PLoS ONE, 2011, 6, e21456.	1.1	50

#	Article	IF	Citations
73	Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomalâ€dominant Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 1251-1260.	0.4	47
74	The Genetic Architecture of Parkinson Disease in Spain: Characterizing Populationâ€Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight. Movement Disorders, 2019, 34, 1851-1863.	2.2	47
75	Tremor dominant parkinsonism: Clinical description and LRRK2 mutation screening. Movement Disorders, 2008, 23, 518-523.	2.2	46
76	MAPT H1 haplotype is associated with enhanced Î±-synuclein deposition in dementia with Lewy bodies. Neurobiology of Aging, 2013, 34, 936-942.	1.5	45
77	Mendelian genes for Parkinson's disease contribute to the sporadic forms of the diseaseâ€. Human Molecular Genetics, 2015, 24, 2023-2034.	1.4	45
78	Regional Overlap of Pathologies in Lewy Body Disorders. Journal of Neuropathology and Experimental Neurology, 2017, 76, 216-224.	0.9	45
79	Cortical microstructure in the behavioural variant of frontotemporal dementia: looking beyond atrophy. Brain, 2019, 142, 1121-1133.	3.7	45
80	Triflusal reduces dense-core plaque load, associated axonal alterations and inflammatory changes, and rescues cognition in a transgenic mouse model of Alzheimer's disease. Neurobiology of Disease, 2010, 38, 482-491.	2.1	44
81	Analysis of known amyotrophic lateral sclerosis and frontotemporal dementia genes reveals a substantial genetic burden in patients manifesting both diseases not carrying the C9orf72 expansion mutation. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 162-168.	0.9	44
82	The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: A data set for biomarker discovery and validation in neurodegenerative disorders. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 597-609.	1.8	44
83	Genetic Cross-Interaction between APOE and PRNP in Sporadic Alzheimer's and Creutzfeldt-Jakob Diseases. PLoS ONE, 2011, 6, e22090.	1.1	43
84	Cerebrospinal Fluid Anti-Amyloid-Î² Autoantibodies and Amyloid PET in Cerebral Amyloid Angiopathy-Related Inflammation. Journal of Alzheimer's Disease, 2016, 50, 1-7.	1.2	43
85	Possible increased risk for Alzheimer's disease associated with neprilysin gene. Journal of Neural Transmission, 2003, 110, 651-657.	1.4	41
86	Homocysteine and Cognitive Impairment. Dementia and Geriatric Cognitive Disorders, 2008, 26, 506-512.	0.7	41
87	Muscle imaging in muscle dystrophies produced by mutations in the EMD and LMNA genes. Neuromuscular Disorders, 2016, 26, 33-40.	0.3	40
88	Association study between Alzheimer?s disease and genes involved in A? biosynthesis, aggregation and degradation: suggestive results with BACE1. Journal of Neurology, 2003, 250, 956-961.	1.8	39
89	Cerebral Amyloid Angiopathy-Related Atraumatic Convexal Subarachnoid Hemorrhage: An ARIA before the Tsunami. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 710-717.	2.4	39
90	A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. Brain, 2018, 141, 2895-2907.	3.7	39

#	Article	IF	Citations
91	Progranulin Protein Levels in Cerebrospinal Fluid in Primary Neurodegenerative Dementias. Journal of Alzheimer's Disease, 2016, 50, 539-546.	1.2	38
92	HSP70-2 (HSPA1B) is Associated with Noncognitive Symptoms in Late-Onset Alzheimer's Disease. Journal of Geriatric Psychiatry and Neurology, 2003, 16, 146-150.	1.2	37
93	Lack of evidence for a genetic association between FGF20 and Parkinson's disease in Finnish and Greek patients. BMC Neurology, 2005, 5, 11.	0.8	37
94	IGF-I gene variability is associated with an increased risk for AD. Neurobiology of Aging, 2011, 32, 556.e3-556.e11.	1.5	36
95	Role for ATXN1, ATXN2, and HTT intermediate repeats in frontotemporal dementia and Alzheimer's disease. Neurobiology of Aging, 2020, 87, 139.e1-139.e7.	1.5	35
96	Investigation of the role of rare TREM2 variants in frontotemporal dementia subtypes. Neurobiology of Aging, 2014, 35, 2657.e13-2657.e19.	1.5	34
97	Methylglyoxal Produced by Amyloid-Î² Peptide-Induced Nitrotyrosination of Triosephosphate Isomerase Triggers Neuronal Death in Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 41, 273-288.	1.2	34
98	Genetic variability in SQSTM1 and risk of early-onset Alzheimer dementia: a European early-onset dementia consortium study. Neurobiology of Aging, 2015, 36, 2005.e15-2005.e22.	1.5	34
99	Exome sequencing in a consanguineous family clinically diagnosed with early-onset Alzheimer's disease identifies a homozygous CTSF mutation. Neurobiology of Aging, 2016, 46, 236.e1-236.e6.	1.5	34
100	Sex differences in the behavioral variant of frontotemporal dementia: A new window to executive and behavioral reserve. Alzheimer's and Dementia, 2021, 17, 1329-1341.	0.4	34
101	Analysis of SCA-2 and SCA-3 repeats in Parkinsonism: Evidence of SCA-2 expansion in a family with autosomal dominant Parkinson's disease. Neuroscience Letters, 2005, 382, 191-194.	1.0	33
102	Early-Onset Familial Lewy Body Dementia With Extensive Tauopathy: A Clinical, Genetic, and Neuropathological Study. Journal of Neuropathology and Experimental Neurology, 2009, 68, 73-82.	0.9	33
103	‹b›Autosomalâ€dominant Alzheimer's disease mutations at the same codon of amyloid precursor protein differentially alter Aî² production‹/b›. Journal of Neurochemistry, 2014, 128, 330-339.	2.1	33
104	Phosphorylated tau181 in plasma as a potential biomarker for Alzheimerâ€™s disease in adults with Down syndrome. Nature Communications, 2021, 12, 4304.	5.8	33
105	MAPT H1 Haplotype is Associated with Late-Onset Alzheimerâ€™s Disease Risk in APOE É›4 Noncarriers: Results from the Dementia Genetics Spanish Consortium. Journal of Alzheimer's Disease, 2015, 49, 343-352.	1.2	32
106	Transethnic meta-analysis of rare coding variants in PLCG2, ABI3, and TREM2 supports their general contribution to Alzheimerâ€™s disease. Translational Psychiatry, 2019, 9, 55.	2.4	32
107	Association of Apolipoprotein E É›4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome. JAMA Neurology, 2021, 78, 937.	4.5	32
108	Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia. Translational Neurodegeneration, 2021, 10, 50.	3.6	32

#	Article	IF	Citations
109	Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease. JAMA Neurology, 2022, 79, 652.	4.5	31
110	Assessing circular RNAs in Alzheimer's disease and frontotemporal lobar degeneration. Neurobiology of Aging, 2020, 92, 7-11.	1.5	30
111	Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1206-1214.	0.9	30
112	Heritability and genetic variance of dementia with Lewy bodies. Neurobiology of Disease, 2019, 127, 492-501.	2.1	29
113	Investigation of Autosomal Genetic Sex Differences in Parkinson's Disease. Annals of Neurology, 2021, 90, 35-42.	2.8	29
114	Reelin Signaling Pathway Genotypes and Alzheimer Disease in a Spanish Population. Alzheimer Disease and Associated Disorders, 2015, 29, 169-172.	0.6	28
115	TREM2 R47H variant and risk of essential tremor: A cross-sectional international multicenter study. Parkinsonism and Related Disorders, 2015, 21, 306-309.	1.1	28
116	Diagnostic and Prognostic Value ofÂtheÂCombination of Two Measures ofÂVerbal Memory in Mild Cognitive Impairment dueÂto Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 58, 909-918.	1.2	28
117	Biphasic cortical macroâ€•and microstructural changes in autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 618-628.	0.4	27
118	Paraoxonase 1 (PON1) gene polymorphisms and Parkinsonâ€™s disease in a Finnish population. Neuroscience Letters, 2004, 367, 168-170.	1.0	26
119	Rare Variants in Calcium Homeostasis Modulator 1 (CALHM1) Found in Early Onset Alzheimerâ€™s Disease Patients Alter Calcium Homeostasis. PLoS ONE, 2013, 8, e74203.	1.1	26
120	Using global team science to identify genetic parkinson's disease worldwide. Annals of Neurology, 2019, 86, 153-157.	2.8	26
121	Downregulation of miR-335-5P in Amyotrophic Lateral Sclerosis Can Contribute to Neuronal Mitochondrial Dysfunction and Apoptosis. Scientific Reports, 2020, 10, 4308.	1.6	26
122	Joint analysis of candidate genes related to Alzheimer's disease in a Spanish population. Psychiatric Genetics, 2003, 13, 85-90.	0.6	25
123	A megalin polymorphism associated with promoter activity and Alzheimer's disease risk. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 895-902.	1.1	24
124	The Effect of MAPT H1 and APOE Îµ4 on Transition from Mild Cognitive Impairment to Dementia. Journal of Alzheimer's Disease, 2011, 22, 1065-1071.	1.2	24
125	Cerebrospinal fluid mitochondrial DNA in the Alzheimer's disease continuum. Neurobiology of Aging, 2017, 53, 192.e1-192.e4.	1.5	24
126	Linkage Disequilibrium and Association Analysis of ?-Synuclein and Alcohol and Drug Dependence in Two American Indian Populations. Alcoholism: Clinical and Experimental Research, 2007, 31, 070212174136004-???.	1.4	23

#	Article	IF	Citations
127	Whole genome analysis in a consanguineous family with early onset Alzheimer's disease. Neurobiology of Aging, 2009, 30, 1986-1991.	1.5	23
128	GSK3Î² polymorphisms, MAPT H1 haplotype and Parkinson's disease in a Greek cohort. Neurobiology of Aging, 2011, 32, 546.e1-546.e5.	1.5	23
129	Rare Variants inPLD3Do Not Affect Risk for Early-Onset Alzheimer Disease in a European Consortium Cohort. Human Mutation, 2015, 36, 1226-1235.	1.1	23
130	Association of theTauhaplotype with Parkinson's disease in the Greek population. Movement Disorders, 2006, 21, 1036-1039.	2.2	22
131	Fused in Sarcoma (FUS) gene mutations are not a frequent cause of essential tremor in Europeans. Neurobiology of Aging, 2013, 34, 2441.e9-2441.e11.	1.5	22
132	A novel PSEN1 mutation (K239N) associated with Alzheimerâ€™s disease with wide range age of onset and slow progression. European Journal of Neurology, 2010, 17, 994-996.	1.7	21
133	HTT gene intermediate alleles in neurodegeneration: evidence for association with Alzheimer's disease. Neurobiology of Aging, 2019, 76, 215.e9-215.e14.	1.5	21
134	Cerebrospinal fluid profile of NPTX2 supports role of Alzheimerâ€™s disease-related inhibitory circuit dysfunction in adults with Down syndrome. Molecular Neurodegeneration, 2020, 15, 46.	4.4	21
135	Detection of genomic rearrangements from targeted resequencing data in Parkinson's disease patients. Movement Disorders, 2017, 32, 165-169.	2.2	19
136	Rare nonsynonymous variants in SORT1 are associated with increased risk for frontotemporal dementia. Neurobiology of Aging, 2018, 66, 181.e3-181.e10.	1.5	19
137	Cortical microstructure in the amyotrophic lateral sclerosisâ€“frontotemporal dementia continuum. Neurology, 2020, 95, e2565-e2576.	1.5	19
138	Parkinson's Disease: From Genetics to Clinical Practice. Current Genomics, 2014, 14, 560-567.	0.7	19
139	Defining the ends of Parkin exon 4 deletions in two different families with Parkinson's disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2005, 133B, 120-123.	1.1	18
140	Phenotypic Variability Within the Inclusion Body Spectrum of Basophilic Inclusion Body Disease and Neuronal Intermediate Filament Inclusion Disease in Frontotemporal Lobar Degenerations With FUS-Positive Inclusions. Journal of Neuropathology and Experimental Neurology, 2012, 71, 795-805.	0.9	18
141	Systematic Screening of Ubiquitin/p62 Aggregates in Cerebellar Cortex Expands the Neuropathological Phenotype of the C9orf72 Expansion Mutation. Journal of Neuropathology and Experimental Neurology, 2018, 77, 703-709.	0.9	18
142	Association of brain-derived neurotrophic factor (BDNF) and elongator protein complex 4 (ELP4) polymorphisms with benign epilepsy with centrotemporal spikes in a Greek population. Epilepsy Research, 2014, 108, 1734-1739.	0.8	17
143	Early diagnosis of amyotrophic lateral sclerosis mimic syndromes: pros and cons of current clinical diagnostic criteria. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 333-340.	1.1	17
144	Elevated YKL-40 and low sAPPÎ²:YKL-40 ratio in antemortem cerebrospinal fluid of patients with pathologically confirmed FTLD. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 180-186.	0.9	17

#	Article	IF	Citations
145	Genetic evaluation of dementia with Lewy bodies implicates distinct disease subgroups. Brain, 2022, 145, 1757-1762.	3.7	17
146	STR data for 21 loci in northwestern Africa. Forensic Science International, 2001, 116, 41-51.	1.3	16
147	Common and rare TBK1 variants in early-onset Alzheimer disease in a European cohort. Neurobiology of Aging, 2018, 62, 245.e1-245.e7.	1.5	16
148	No supportive evidence for TIA1 gene mutations in a European cohort of ALS-FTD spectrum patients. Neurobiology of Aging, 2018, 69, 293.e9-293.e11.	1.5	15
149	Genetic variability of the gene cluster CALHM1â€“3 in sporadic Creutzfeldt-Jakob disease. Prion, 2012, 6, 407-412.	0.9	14
150	Dystonia and the Nuclear Envelope. Neuron, 2005, 48, 875-877.	3.8	13
151	Association of phosphodiesterase 4D gene G0 haplotype and ischaemic stroke in a Greek population. European Journal of Neurology, 2007, 14, 745-749.	1.7	13
152	Expansion mutation in C9ORF72 does not influence plasma progranulin levels in frontotemporal dementia. Neurobiology of Aging, 2012, 33, 1851.e17-1851.e19.	1.5	13
153	Copy number variation analysis of the 17q21.31 region and its role in neurodegenerative diseases. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2016, 171, 175-180.	1.1	13
154	APPâ€derived peptides reflect neurodegeneration in frontotemporal dementia. Annals of Clinical and Translational Neurology, 2019, 6, 2518-2530.	1.7	13
155	A comprehensive screening of copy number variability in dementia with Lewy bodies. Neurobiology of Aging, 2019, 75, 223.e1-223.e10.	1.5	13
156	Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies. Neurobiology of Aging, 2017, 49, 214.e13-214.e15.	1.5	12
157	Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimerâ€™s Disease Cerebrospinal Fluid Biomarkers. Journal of Alzheimer's Disease, 2018, 66, 639-652.	1.2	12
158	Diagnostic Utility of Measuring Cerebral Atrophy in the Behavioral Variant of Frontotemporal Dementia and Association With Clinical Deterioration. JAMA Network Open, 2021, 4, e211290.	2.8	12
159	LRP10 in Î±-synucleinopathies. Lancet Neurology, The, 2018, 17, 1032-1033.	4.9	11
160	Assessment of PINK1 (PARK6) polymorphisms in Finnish PD. Neurobiology of Aging, 2006, 27, 906-907.	1.5	10
161	PICOGEN: Five years experience with a genetic counselling program for dementia. NeurologÃa (English) Tj ETQq1 1 0.784314 rgBT /O	0.2	10
162	A Common BACE1 Polymorphism Is a Risk Factor for Sporadic Creutzfeldt-Jakob Disease. PLoS ONE, 2012, 7, e43926.	1.1	10

#	Article	IF	Citations
163	Comparison of 2 Diagnostic Criteria for the Behavioral Variant of Frontotemporal Dementia. American Journal of Alzheimer's Disease and Other Dementias, 2013, 28, 469-476.	0.9	10
164	Heterozygous APOE Christchurch in familial Alzheimerâ€™s disease without mutations in other Mendelian genes. Neuropathology and Applied Neurobiology, 2021, 47, 579-582.	1.8	10
165	Gene Expression Imputation Across Multiple Tissue Types Provides Insight Into the Genetic Architecture of Frontotemporal Dementia and Its Clinical Subtypes. Biological Psychiatry, 2021, 89, 825-835.	0.7	10
166	Unique post-exercise electrophysiological test results in a new Andersenâ€“Tawil syndrome mutation. Clinical Neurophysiology, 2011, 122, 2537-2539.	0.7	9
167	Assessing the role of TUBA4A gene in frontotemporal degeneration. Neurobiology of Aging, 2016, 38, 215.e13-215.e14.	1.5	9
168	Cognitive decline in amyotrophic lateral sclerosis: Neuropathological substrate and genetic determinants. Brain Pathology, 2021, 31, e12942.	2.1	9
169	Prion-like Î±-synuclein pathology in the brain of infants with Krabbe disease. Brain, 2022, 145, 1257-1263.	3.7	9
170	Leveraging large multi-center cohorts of Alzheimer disease endophenotypes to understand the role of Klotho heterozygosity on disease risk. PLoS ONE, 2022, 17, e0267298.	1.1	9
171	Early Cerebellar Hypometabolism in Patients With Frontotemporal Dementia Carrying the C9orf72 Expansion. Alzheimer Disease and Associated Disorders, 2015, 29, 353-356.	0.6	8
172	Genetic variation in APOE, GRN, and TP53 are phenotype modifiers in frontotemporal dementia. Neurobiology of Aging, 2021, 99, 99.e15-99.e22.	1.5	8
173	Lack of Association of thePICALMrs3851179 Polymorphism With Parkinson's Disease in the Greek Population. International Journal of Neuroscience, 2012, 122, 502-605.	0.8	6
174	Long runs of homozygosity are associated with Alzheimerâ€™s disease. Translational Psychiatry, 2021, 11, 142.	2.4	6
175	VAMP-2 is a surrogate cerebrospinal fluid marker of Alzheimer-related cognitive impairment in adults with Down syndrome. Alzheimer's Research and Therapy, 2021, 13, 119.	3.0	6
176	A Common Variant in the MC1R Gene (p.V92M) is associated with Alzheimerâ€™s Disease Risk. Journal of Alzheimer's Disease, 2017, 56, 1065-1074.	1.2	5
177	Cerebrospinal fluid mitochondrial DNA levels in patients with multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1535-1538.	1.4	5
178	Genetic architecture of neurodegenerative dementias. Neuropharmacology, 2020, 168, 108014.	2.0	5
179	Comparative Analysis of Alu Insertion Sequences in the APP 5â€² FlankingRegion in Humans and Other Primates. Journal of Molecular Evolution, 2004, 58, 722-731.	0.8	4
180	Mutation of the Parkin gene in a Persian family: Clinical progression over a 40-year period. Movement Disorders, 2005, 20, 887-890.	2.2	4

#	Article	IF	Citations
181	Using the Neandertal and Denisova Genetic Data to Understand the Common MAPT 17q21 Inversion in Modern Humans. Human Biology, 2012, 84, 633-640.	0.4	4
182	O5â€02â€04: DOWN ALZHEIMER BARCELONA NEUROIMAGING INITIATIVE (DABNI): A PROSPECTIVE LONGITUDINAL BIOMARKER COHORT TO STUDY ALZHEIMERâ€™S DISEASE IN DOWN SYNDROME. Alzheimer's and Dementia, 2016, 12, P380.	0.4	4
183	Distinct Clinical Features and Outcomes in Motor Neuron Disease Associated with Behavioural Variant Frontotemporal Dementia. Dementia and Geriatric Cognitive Disorders, 2018, 45, 220-231.	0.7	4
184	Mendelian randomization implies no direct causal association between leukocyte telomere length and amyotrophic lateral sclerosis. Scientific Reports, 2020, 10, 12184.	1.6	4
185	Developmental Dynamic Dysphasia: Are Bilateral Brain Abnormalities a Signature of Inefficient Neural Plasticity?. Frontiers in Human Neuroscience, 2020, 14, 73.	1.0	4
186	Sex differences in the behavioral variant of frontotemporal dementia: A new window to executive and behavioral reserve. Alzheimer's and Dementia, 2021, 17, .	0.4	4
187	Myelin loss in C9orf72 hexanucleotide expansion carriers. Journal of Neuroscience Research, 2022, 100, 1862-1875.	1.3	4
188	Lack of Association Between CX3CR1 V249I and T280M Polymorphisms and Risk of Parkinson's Disease in a Greek Population. Genetic Testing and Molecular Biomarkers, 2012, 16, 974-977.	0.3	3
189	Effect of <scp>REST</scp> on brain metabolism in the Alzheimer disease continuum. Annals of Neurology, 2015, 78, 661-662.	2.8	2
190	Genetic and Epigenetic Architecture of Alzheimerâ€™s Dementia. Current Genetic Medicine Reports, 2016, 4, 7-15.	1.9	2
191	Conjoint FTLDâ€FUS of the neuronal intermediate filament inclusion disease type, progressive supranuclear palsy and Alzheimer's pathology presenting as parkinsonism with early falls and late hallucinations, psychosis and dementia. Neuropathology and Applied Neurobiology, 2017, 43, 352-357.	1.8	2
192	Absence of pathogenic mutations in CD59 in chronic inflammatory demyelinating polyradiculoneuropathy. PLoS ONE, 2019, 14, e0212647.	1.1	2
193	Genetic-environmental factors finally assessed together in Parkinsonâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1030-1030.	0.9	2
194	Smoking is associated with age at disease onset in Parkinson's disease. Parkinsonism and Related Disorders, 2022, 97, 79-83.	1.1	2
195	Title is missing!. Psychiatric Genetics, 2003, 13, 85-90.	0.6	1
196	SORL1 â€variant carriers in ADESâ€ADSP: A higher level of variant pathogenicity associates with earlier age at onset of Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e044492.	0.4	1
197	Neuropathology of a patient with Alzheimer disease treated with low doses of verubecestat. Neuropathology and Applied Neurobiology, 2022, 48, .	1.8	1
198	Exome sequencing identifies rare damaging variants in the ATB8B4 and ABCA1 genes as novel risk factors for Alzheimer's disease.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e055982.	0.4	1

#	Article	IF	Citations
199	P3-230: CSF Î²-AMYLOID AND PHOSHO-TAU INTERACTIONS ON BRAIN STRUCTURE IN PRECLINICAL AD. , 2014, 10, P715-P715.		0
200	P2-132: BIOMARKERS IN CEREBRAL AMYLOID ANGIOPATHY-RELATED INFLAMMATION. , 2014, 10, P519-P519.		0
201	P1-121: Comparison of different ÃŸ-amyloid isoforms in CSF to detect amyloid pathology in cognitively normal subjects and patients with dementia. , 2015, 11, P387-P387.		0
202	P2-424: Obesity is Associated With Increased CSF Phospho-TAU Levels and Cognitive Decline in Healthy Elderly. , 2016, 12, P807-P807.		0
203	Incidental neuronal intermediate filament inclusion pathology: unexpected biopsy findings in a 37â€yearâ€old woman with epilepsy. Neuropathology and Applied Neurobiology, 2017, 43, 636-640.	1.8	0
204	[P1â€“366]: WEIGHT LOSS MIGHT BE A NONâ€COGNITIVE SIGN OF PRECLINICAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P399.	0.4	0
205	P2â€262: A CEREBROSPINAL FLUID PANEL OF SYNAPTIC PROTEINS ACROSS THE ENTIRE ALZHEIMER'S DISEASE CONTINUUM. Alzheimer's and Dementia, 2018, 14, P777.	0.4	0
206	P1â€293: IDENTIFICATION OF EXOSOMAL MICRORNAS AS POTENTIAL DIAGNOSTIC BIOMARKERS FOR FRONTOTEMPORAL DEMENTIA. Alzheimer's and Dementia, 2018, 14, P398.	0.4	0
207	ICâ€Pâ€148: THE CORTICAL MICROSTRUCTURAL SIGNATURE OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P119.	0.4	0
208	O2â€09â€01: THE NATURAL HISTORY OF ALZHEIMER'S DISEASE IN DOWN SYNDROME. Alzheimer's and Dementia, 2019, 15, P558.	0.4	0
209	Oligodendroglial alterations in FTD caused by C9orf72 expansion. Alzheimer's and Dementia, 2020, 16, e040196.	0.4	0
210	Transcriptome characterization of the motor cortex suggests microglialâ€related key events due to TDPâ€43 aberrant inclusions. Alzheimer's and Dementia, 2020, 16, e042953.	0.4	0
211	1 Hâ€MRS signature in Alzheimer disease in Down syndrome. Alzheimer's and Dementia, 2020, 16, e043346.	0.4	0
212	VAMP2 is a cerebrospinal fluid marker of selective hippocampal synapse loss and episodic memory performance in Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e045268.	0.4	0
213	A multimodal study on the effect of sex on Alzheimer's disease clinical and biomarker changes in adults with Down syndrome. Alzheimer's and Dementia, 2021, 17, .	0.4	0
214	Plasma biomarkers for the AT(N) classification and for the detection of Alzheimerâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.4	0
215	Transcriptome-wide characterization of the frontal cortex in FTLD.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e049569.	0.4	0